Spotlight Innovation Signs Letter of Intent to Acquire Memcine Pharmaceuticals

Memcine Pharmaceuticals' Immunoplex Vaccine Platform Technology Has Broad Applicability in Both Infectious Diseases and Oncology Immunotherapy

WEST DES MOINES, IA--(Marketwired - Oct 14, 2014) - Spotlight Innovation Inc. (OTCQB: STLT) announced that it has signed a Letter of Intent to acquire majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex™ vaccine platform technology, which is designed to use the body's own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response.

Cris Grunewald, President and CEO of Spotlight Innovation, said, "Memcine Pharmaceuticals' mission directly supports Spotlight Innovation's goal of positively impacting the health and well-being of as many people as possible. Memcine Pharmaceuticals' Immunoplex technology has shown enormous potential with broad applicability in both infectious diseases and oncology immunotherapy. We look forward to closing this transaction, furthering the development and fulfilling the promise of this exciting, potentially life-saving technology."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) specializes in identifying, acquiring and incubating companies which have unique intellectual property (IP) in the medical sector. The Company utilizes relationships with the nation's leading academic and institutional IP developers to locate promising IP technologies with potential for market share capture. With our support, development resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We intend to partner with proven sector leaders on commercialization once technologies are fully developed. Additional information available at

About Memcine Pharmaceuticals Inc.

Memcine Pharmaceuticals Inc. is an early-stage biotech company focused on enhancing vaccine efficacy to improve human and animal health globally. Memcine's Immunoplex™ technology platform uses the body's naturally occurring targeting system to deliver vaccine components. The current portfolio of potential infectious disease vaccine targets includes influenza, HepB, and Ebola. Memcine Pharmaceuticals has also conducted pre-clinical experiments in a mouse model of breast cancer, where the vaccine technology showed considerable promise as a therapeutic treatment. Additional information available at

Forward Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact Information

Press Contact
Rene Erickson
Spotlight Innovation Inc.

Investor Relations Contact
Mike Reysack
Spotlight Innovation Inc.

To read more Press Release articles, click here.